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Dopamine induces the expression of heme oxygenase-1 by dopamine (DA) and/or norepinephrine resulted in supe-
human endothelial cells in vitro. rior graft survival in long-term follow-up [1]. Interest-
Background. In a retrospective study of the kidney trans- ingly, the majority of clinical studies examining the effectplantations performed at our institution, we found that the
of DA administration following transplantation haveadministration of dopamine (DA) to the organ donors resulted
failed to show a beneficial effect [2–4].in a significant improvement of long-term organ survival of the
retrieved kidneys. To study the mechanisms underlying the In searching for an explanation for the protective ef-
organ protection associated with the administration of DA prior fect of DA administration prior to transplantation, we
to transplantation, we questioned whether DA induces the anti- wondered how catecholamine pretreatment may protectoxidative enzyme heme oxygenase-1 (HO-1) in cultured endo-
the organs from the insult of ischemia/reperfusion injury.thelial cells.
Methods. Human umbilical vein endothelial cells (HUVECs) A possible mechanism may be via the induction of anti-
in culture were incubated with varying concentrations of DA oxidant enzymes such as heme oxygenase-1 (HO-1). HO-1
for different time periods. Cells were subsequently assessed for is an oxygen stress-inducible heat shock protein thatthe expression of HO-1 by Western blot and semiquantitative
catalyzes the oxidation of heme to biliverdin, iron, andreverse transcription-polymerase chain reaction (RT-PCR).
carbon monoxide [5]. Via this mechanism, HO-1 removesResults. The presence of DA resulted in a dose- and time-
dependent up-regulation of HO-1 both on RNA and protein pro-oxidant destabilized heme molecules and generates
level, whereas HO-1 was barely detectable under basal condi- the antioxidant bilirubin [6]. The induction of HO-1 has
tions. RT-PCR indicated the increased presence of HO-1 mes- been associated with a protective effect in models ofsenger RNA after 2 hours of incubation with DA, which peaked
heme-induced renal failure [7, 8], and the presence ofafter 24 hours. The induction of HO-1 antigen was detectable
after eight hours, as visualized by Western blot analysis. The HO-1 has been linked to the prevention of chronic allo-
addition of the antioxidant agents ascorbic acid and N-acetyl- graft rejection and improved xenograft survival in animal
cysteine both lead to dose-dependent inhibition of DA-medi- transplant models [9, 10].ated HO-1 induction. DA-mediated up-regulation of HO-1 was
Since HO-1 is up-regulated by oxidative stress, andnot influenced by the addition of either the D2-receptor antago-
catecholamines (especially DA) are known to be power-nist haloperidol or the D1-receptor antagonist SCH 23390.
Conclusion. We conclude that DA induces the expression ful pro-oxidants [11, 12], we questioned whether DA
of the protective enzyme HO-1 in cultured endothelial cells may be capable of inducing HO-1 in endothelial cells.
by an oxidative mechanism. These findings may explain the
beneficial effect of DA administration to kidney donors and
indicate the potential role of DA in organ preconditioning. METHODS
Reagents
In a center-based case control study to identify donor- The following reagents were used: DA (Fresenius, Bad
specific determinants affecting outcome in renal trans- Homburg, Germany); haloperidol (Janssen-Cilag GMBH,
plantation, we showed that both donor treatment with Neuss, Germany); ascorbic acid, KCl, ammonium sulfate
(all Merck, Darmstadt Germany); hemin, SCH 23390,
collagenase V, trypsin, penicillin-streptomycin, HEPES,Key words: transplantation, organ preconditioning, antioxidant, hu-
man umbilical vein endothelial cells, kidney donor. egtazic acid (EGTA), ethylenediaminetetraacetic acid
(EDTA), phenylmethylsulfonyl fluoride (PMSF), Igpal,Received for publication October 22, 1999
Tris HCl, and MgCl (all from Sigma, St. Louis, MO, USA);and in revised form June 20, 2000
Accepted for publication June 26, 2000 medium M199, phosphate-buffered saline (PBS), fetal calf
serum (FCS), endothelial cell growth factor, TRIZOLÓ 2000 by the International Society of Nephrology
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Reagent, random primers, Taq DNA-polymerase, dithio- assessed for the expression of HO-1 antigen by Western
blot.threitol (DTT), dNTP (all from GIBCO BRL, Grand Is-
land, NY, USA); primers (GAPDH and HO-1), oligo dT
Inhibition with antioxidants(all Perkin Elmer, Weiterstadt, Germany); gelatin (Fluka,
Buchs, Switzerland); Coomassie Blue reagent (Pierce, Human umbilical vein endothelial cells were treated
with medium alone or medium containing DA (10 mg/mL)Rockford, IL, USA); polyvinylidene difluoride (PVDF)
membrane (Boehringer, Mannheim, Germany); rab- in the presence or absence of increasing doses of either
NAC (N-acetyl cysteine; 0.1 to 500 mg/mL) or ascorbicbit-anti-HO-1 antibody (StressGen, Victoria, Canada);
horseradish peroxide-conjugated goat-antirabbit anti- acid (0.5 to 500 mg/mL) for 16 hours. Cells were har-
vested after 16 hours and assessed for the expression ofbody (Santa Cruz, Heidelberg, Germany); chemilumines-
cence reagent (Life Science Products, Boston, MA, USA); HO-1 antigen or mRNA by Western blot and RT-PCR,
respectively.BIO-MAX Film (Kodak, Rochester, NY, USA); and
factor VIII-related antigen (Dako, High Wycombe, UK).
RNA isolation and RT-PCR analysis
Cell culture Total RNA was isolated using TRIZOL reagent ac-
cording to the manufacturer’s instructions. Two micro-Human umbilical vein endothelial cells (HUVECs)
were prepared from fresh umbilical cords according to grams of total RNA was reverse transcribed into cDNA
by oligo-dT and random hexamer priming. Deoxy-oligo-the method described by Jaffe et al [13]. Briefly, endothe-
lial cells were isolated from umbilical veins by digestion nucleotide primers were constructed from the published
cDNA sequence of HO-1 [14] and GAPDH [15] andwith collagenase V for 20 minutes at 378C. Thereafter,
the vein was flushed with sterile medium to collect endo- resulted in 284 and 268 bp products, respectively. GAPDH
controls were performed for all PCRs. The sequences ofthelial cells. The culture medium consisted of medium
199 supplemented with 10% FCS, endothelial cell growth the primers were as follows: HO-1 forward, GCT CAA
CAT CCA GCT CTT TGA GG; HO-1 reverse, GACfactor, and penicillin-streptomycin. The cells were cul-
tured in 25 or 75 cm2 flasks coated with 1% gelatin. Con- AAA GTT CAT GGC CCT GGG A; GAPDH forward,
GTC TTC ACC ACC ATG GAG AA; and GAPDHfluent cells were harvested with 0.02% EDTA/0.05% tryp-
sin and were subcultured in T25 flasks. reverse, ATC CAC AGT CTT CTG GGT GG.
Amplification of cDNA by PCR was performed by aAll experiments were performed with cells from pas-
sages two to six. HUVECs were characterized on the modification of the procedure described by Saiki et al
[16] One microliter of cDNA, 20 pmol of each primer,basis of positive staining for factor VIII-related antigen
and the endothelial marker EN4 (CD31). and 0.5 pmol Taq-DNA-polymerase were added to a final
volume of 50 mL (for HO-1, 75 mmol/L KCl, 10 mmol/L
Dopamine and norepinephrine stimulation Tris-HCl, pH 8.8, 1.5 mmol/L MgCl2, 0.25 mmol/L of
each dNTP; for GAPDH, 15 mmol/L KCl, 10 mmol/LAll experiments were performed with confluent mono-
layers of HUVECs, seeded in T25 culture flasks. HUVECs Tris-HCl, pH 8.9, 1.5 mmol/L MgCl2, 75 mmol/L ammo-
nium sulfate, 0.25 mmol/L of each dNTP). The mixturewere treated with concentrations of 0.1, 1, 10, 50, and
100 mg/mL of DA or norepinephrine in complete culture was heated at 958C for three minutes followed by 27
(HO-1) or 30 (GAPDH) cycles, each consisting of incu-medium. Cells were harvested after 16 hours and were
assessed for the induction of HO-1 by reverse transcrip- bation for one minute at 958C, one minute at 628C (HO-1)
or 598C (GAPDH), and two minutes at 728C. After ter-tion-polymerase chain reaction (RT-PCR) and Western
blot. Cells were incubated with hemin at 5 mmol/L as a mination of the last cycle, the samples were chilled at 48C.
Polymerase chain reaction products were separatedpositive control for HO-1 induction.
The kinetics of DA-mediated HO-1 induction were by electrophoresis on a 1% agarose ethidium bromide
gel. Identity of the bands was confirmed by sequencingstudied by incubation of HUVECs with medium or me-
dium containing DA (10 mg/mL). Cells were harvested on a ABI 310 automatic sequencer. The semiquantitative
character of the PCR was ascertained by twofold serialat various time points, and HO-1 induction was assessed
by Western blot and RT-PCR. dilutions of cDNA and controlled for equal expression
of the GAPDH PCR product.
Inhibition with DA receptor antagonists
Western blot analysisTo study the mechanism of DA-induced HO-1 expres-
sion, HUVECs were treated with medium alone or me- Human umbilical vein endothelial cell monolayers
were harvested with trypsin EDTA, and subsequently,dium containing DA (10 mg/mL) in the presence or absence
of increasing doses of either haloperidol (1 to 10 mg/mL) the cell pellet was washed twice in ice-cold PBS. Cyto-
plasmatic proteins were isolated by adding 100 mL of lysisor SCH 23390 (0.05 to 50 mg/mL). Cells were harvested
after 16 hours. Cytoplasmic proteins were isolated and buffer containing 10 mmol/L HEPES, pH 7.9, 10 mmol/L
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Fig. 1. Dopamine (DA)-mediated up-regulation of heme oxygenase-1
(HO-1) mRNA in human umbilical vein endotheial cells (HUVECs). Fig. 2. DA-mediated up-regulation of HO-1 protein in HUVECs. Cells
Cells were incubated with medium alone (lane 1), Hemin 5 mmol/L were incubated with medium alone (lane 2), Hemin 5 mmol/L (lane 3),
(lane 2), DA 0.1 mg/L (lane 3), DA 1 mg/mL (lane 4), DA 10 mg/mL DA 0.1 mg/L (lane 4), DA 1 mg/mL (lane 5), DA 10 mg/mL (lane 6),
(lane 5), DA 50 mg/mL (lane 6), DA 100 mg/mL (lane 7). After 16 DA 50 mg/mL (lane 7), DA 100 mg/mL (lane 8). Lane 1 shows a
hours, mRNA was isolated and assessed by RT-PCR for the expression molecular weight ladder. After 16 hours of incubation, HUVECs were
of HO-1 and GAPDH. Data are representative of three independently harvested, and Western blot analysis was performed using a polyclonal
performed experiments. anti-HO-1 antibody. HO-1 is identified as a 32 kD protein. Data are
representative of three independently performed experiments.
KCl, 0.1 mmol/L EGTA, 0.1 mmol/L EDTA, 1 mmol/L
DTT, 0.5 mmol/L PMSF, and 12.5 mL of 10% Igpal,
followed by centrifugation (12,000 g) to remove undis-
solved debris. Protein concentrations of the supernatants
were determined by the Coomassie Blue assay. Twenty-
five micrograms of total protein was then separated on
10% SDS-PAGE according to Laemmli [17] and semidry
blotted on a PVDF membrane. The membrane was incu-
bated overnight in 5% milk powder in TBS (10 mmol/L
Tris-HCl, pH 8.0, 150 mmol/L NaCl) solution.
Thereafter, the blot was incubated for one hour with
polyclonal rabbit-anti-HO-1 antibodies. After washing, the
blot was incubated with HRP conjugated goat-anti-rabbit-
IgG antibodies for 30 minutes. Antibody binding was
Fig. 3. Kinetics of DA-mediated induction of HO-1 in HUVECs.visualized by chemiluminescence on a BIO-MAX film.
HUVECs were incubated in the presence (1) or absence (2) of DA
(10 mg/mL). Cells were harvested at various time intervals and were
assessed for HO-1 by either RT-PCR (A) or Western blot (B).RESULTS
To examine the effect of DA on the expression of
HO-1 by endothelial cells, HUVECs were exposed to
level was examined by Western blot (Fig. 2) and showedincreasing doses of DA. Hemin at a dose of 5 mmol/L
a corresponding induction of HO-1 antigen.served as a positive control. mRNA was isolated after
The kinetics of HO-1 up-regulation was determined16 hours and analyzed for HO-1 expression by semiquan-
using DA 10 mg/mL and incubation of endothelial cellstitative RT-PCR. While HO-1 mRNA was barely detect-
for up to 72 hours. Cells were harvested and assessedable under basal conditions, the addition of DA resulted
for HO-1 mRNA by RT-PCR and for HO-1 antigen byin a dose-dependent increase in the expression of HO-1
Western blot. As shown in Figure 3A, an increase inclearly detectable at a DA dose of 1 mg/mL and with a
HO-1 mRNA was detectable after 2 hours and peakedmaximum at a DA concentration of 50 mg/mL (Fig. 1).
after 6 to 12 hours. HO-1 antigen was detectable afterDA concentrations above 100 mg/mL resulted in detach-
8 hours of incubation with DA and increased for up toment of the cells. No induction of HO-1 was detected
when HUVECs were treated with norepinephrine in a 48 hours as demonstrated by Western blot (Fig. 3B).
To assess the mechanism of DA-mediated HO-1 up-range of 0.1 to 200 mg/mL (data not shown). A twofold
serial dilution of cDNA obtained from HUVECs treated regulation, HUVECs were treated with DA in the pres-
ence of either the D1-receptor antagonist SCH 23390with DA (10 mg/mL) for 16 hours demonstrated a four-
fold induction of HO-1 mRNA when compared with or the D2-receptor antagonist haloperidol. As shown in
Figure 4, neither increasing doses of SCH 23390 (0.1 tocDNA obtained from cells treated with medium alone
(data not shown). The up-regulation of HO-1 on protein 100 mg/mL) or haloperidol (0.1 to 10 mg/mL) influenced
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Fig. 4. Addition of DA-receptor antagonists haloperidol and SCH
23390. HUVEC were incubated with medium alone, DA (10 mg/mL),
or DA (10 mg/mL) in the presence of increasing doses of either haloperi- Fig. 6. Inhibition of DA mediated HO-1 induction by NAC. HUVECs
dol (A) or SCH 23390 (B). Cells were harvested after 16 hours and were incubated with medium alone, DA (10 mg/mL) or DA (10 mg/mL)
were assessed for the expression of HO-1 by Western blot. Data are in the presence of increasing doses NAC. After 16 hours, mRNA was
representative of three independently performed experiments. isolated and assessed by RT-PCR for the expression of HO-1 and
GAPDH (A). Western blot analysis of HUVECs incubated for 16
hours as described (B). Data are representative of three independent
experiments.
ure 6, the addition of NAC to DA stimulated HUVECs
leads to a complete abrogation of HO-1 induction on
both protein and mRNA levels.
DISCUSSION
This article demonstrates the induction of the endo-
thelial synthesis of HO-1 by DA in vitro. The DA dose
of 1 mg/mL, which leads to a powerful induction of both
HO-1 RNA and protein in the dose response experi-
ments, is within the upper range of therapeutic steady-
state DA levels measured in patients receiving interme-
Fig. 5. Inhibition of DA-mediated HO-1 induction by ascorbic acid. diate dose DA treatment [18, 19]. Our data demonstrateHUVECs were incubated with medium alone, DA (10 mg/mL), or DA
that DA exerts its effect via an oxidative mechanism.(10 mg/mL) in the presence of increasing doses ascorbic acid. After 16
hours, mRNA was isolated and assessed by RT-PCR for the expression While the DA-mediated induction of HO-1 was not in-
of HO-1 and GAPDH (A). Western blot analysis of HUVECs treated fluenced by the addition of the D2-receptor antagonistas described (B). Data are representative of three independent experi-
haloperidol or the specific D1-receptor antagonist SCHments.
23390, the induction of both HO-1 mRNA and antigen
was inhibited by the addition of the antioxidant vitamin C
and completely blocked in the presence of NAC.the DA-mediated up-regulation of HO-1, as detected by
Heme oxygenase-1 is induced by a broad spectrum ofWestern blot analysis. The treatment of HUVECs with
oxidative agents [5]. However, to our knowledge, this iseither SCH 23390 or haloperidol alone at the maximum
the first time a commonly used drug is reported as adoses that did not result in visible cellular toxicity did
powerful HO-1 inducer. Furthermore, the association ofnot influence the expression of HO-1 (data not shown).
donor DA administration with an improved outcome inSince we speculated that DA may exert its effect on
renal transplantation underscores the relevance of ourthe expression of HO-1 by an oxidative mechanism, we
findings.examined the effect of the antioxidant agents vitamin C
Possible oxidative effects of DA have generated aand N-acetyl-cysteine (NAC) on the expression of HO-1
strong interest in the context of Parkinson’s disease andby DA stimulated HUVECs. Both RT-PCR and West-
schizophrenia [11, 20]. The auto-oxidation of DA in theern blot for HO-1 showed that the addition of vitamin C
presence of transition metals, for example, iron or cop-to a fixed dose of DA (10 mg/mL) leads to a dose-depen-
per, leads to the generation of quininones/semiquinonesdent although not complete inhibition of the DA-medi-
ated up-regulation of HO-1 (Fig. 5). As depicted in Fig- and reactive oxygen species, including the superoxide
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radical (O22) and hydrogen peroxide (H2O2) [12]. DA or gene therapy prevent ischemia/reperfusion injury in
livers of genetically fat Zucker rats [29]. The inhibitionhas been shown to induce apoptosis in neuroneal cell lines
via oxidative mechanisms. Treatment of mesencephalic of HO-1 with tin mesoporphyrin markedly worsens renal
failure in a model of ischemic renal failure [30]. Thecell cultures with nontoxic levels of the auto-oxidizable
compound L-DOPA leads to resistance to the toxic ef- protective effects of HO-1 have been linked to the action
of bilirubin [31, 32].fects of the strong oxidant tert-butyl hydroperoxide [21].
In our experiments, no up-regulation of HO-1 was ob- Thus, the induction of protective genes such as HO-1
prior to transplantation may provide the organ with aserved when HUVECs were treated with norepineph-
rine. This is in keeping with a weaker toxic effect of resistance to the insult of ischemia/reperfusion and in-
flammation that results in the improved outcome ob-norepinephrine compared with DA [22].
A recent retrospective study of the cadaveric kidney served after donor DA administration. Since ischemia/
reperfusion is thought to have a strong impact on thetransplantations performed at our center showed that the
administration of DA to the organ donors prior to trans- development of acute and chronic rejection [33], the
reduction of reperfusion injury is a major task in trans-plantation leads to a significant reduction of acute graft
rejection episodes and improvement of long-term sur- plant medicine. A possible approach is the emerging
concept of organ preconditioning [34]. Short periods ofvival [1]. Studies on the administration of DA after renal
transplantation have either failed to demonstrate an ef- ischemic stress render the organ (for example, the heart)
resistant to a subsequent episode of prolonged ischemia.fect [2–4] or report an adverse association between donor
catecholamine use and immediate graft function [23, 24]. Two distinct phases of protection have been identified.
The early phase develops within minutes and has beenIt has been demonstrated that E-selectin, intercellular
adhesion molecule-1, and vascular cell adhesion mole- linked to the release of adenosine [35]. The second phase
is referred to as late preconditioning and takes hours tocule-1 are up-regulated in models of brain injury and
cerebral ischemia [25, 26]. The pretreatment of HUVECs become apparent. The generation of reactive oxygen spe-
cies is an essential component [36], and the induction ofwith the inotropes amrinone and DA leads to an inhibi-
tion of IL-1b–mediated up-regulation of adhesion mole- nuclear factor-kB and nitric oxide synthase are both neces-
cules [27]. Thus, possibly the down-regulation of elevated sary for the development of organ protection [37, 38].
adhesion molecules in the transplanted grafts may contrib- Our results indicate that DA may provide its beneficial
ute to the beneficial effect of donor treatment with DA. effect in renal transplantation by pharmacological pre-
However, an inhibition of adhesion molecules by cate- conditioning with the induction of antioxidative and pos-
cholamines would not explain why the administration of sibly anti-inflammatory genes. The powerful pro-oxida-
DA after the transplantation procedure has not proven tive effects may also explain why the administration of
to be beneficial. The timely induction of protective genes DA after transplantation is of no benefit or may even
prior to the actual ischemia/reperfusion insult may be an be harmful. DA given during the phase of reperfusion
alternative explanation. Of these genes, HO-1 is a possible may lead to additional oxidative stress with glutathione
candidate. HO-1 is a 32 kD microsomal enzyme that has and NO depletion, resulting in increased damage and
been linked to a protective effect in a broad variety of possibly immunogenicity of the transplanted organ.
disease models. It catalyzes the conversion of heme to Although of obvious importance, the induction of HO-1
biliverdin, iron, and carbon monoxide (CO) [5]. Via this of course may not be the only beneficial gene induced
mechanism, HO-1 degrades destabilized potentially in response to DA-mediated oxidative stress. Further
toxic heme molecules and generates biliverdin, which is studies are required to determine whether other candi-
subsequently converted to the antioxidant bilirubin [6]. date genes such as superoxide dismutase, glutathione,
The iron released during this process is sequestered by nitric oxide synthetase, or catalase are induced by DA.
ferritin, which is induced together with HO-1 [28]. An Furthermore, although ample evidence of oxidative me-
additional beneficial effect may arise from the synthesis tabolism of cathecholamines in the brain exists [11], we
of CO, which similar to NO is a potent vasodilator [5]. do not know whether DA administered in vivo is oxi-
In vivo models of renal disease have underscored the dized sufficiently to induce the stress necessary for the
potential protective role of HO-1. The induction of HO-1 HO-1 induction observed in our in vitro system. Studies
confers resistance to the development of renal failure in to examine the induction of HO-1 by DA and its effect
glycerol-induced rhabdomyolysis in the rat [7, 8]. Recent on ischemia/reperfusion injury in the presence of the
studies have demonstrated that the expression of HO-1 antioxidative armamentarium of the living organism are
is linked to an improved outcome both in models of underway.
xenotransplantation and chronic rejection [9, 10]. A
Reprint requests to Stefan P. Berger, M.D., Department of Generalnumber of recent studies indicate an important protec-
Internal Medicine, Leiden University Medical Center, Rijnsburgerweg
tive of HO-1 in the setting of ischemia/reperfusion. Both 10, Postbus 9600, 2300RC Leiden, The Netherlands.
E-mail: s.p.berger@lumc.nlthe induction of HO-1 with either cobalt protoporphyrin
Berger et al: Dopamine in HUVECs 2319
21. Han SK, Mytilineou C, Cohen G: L-DOPA up-regulates glutathi-REFERENCES
one and protects mesencephalic cultures against oxidative stress.
J Neurochem 66:501–510, 19961. Schnuelle P, Lorenz D, Mueller A, Trede M, Van Der Woude
FJ: Donor catecholamine use reduces acute allograft rejection and 22. Kawase M, Motohashi N, Kurihara T, Inagaki M, Satoh K,
Sakagami H: Relationship between radical intensity and cytotoxicimproves graft survival after cadaveric renal transplantation. Kid-
ney Int 56:738–746, 1999 activity of dopamine-related compounds. Anticancer Res 18:1069–
1074, 19982. Sandberg J, Tyden G, Groth CG: Low-dose dopamine infusion
following cadaveric renal transplantation: No effects on the inci- 23. O’Brien EA, Bour SA, Marshall RL, Ahsan N, Yang HC: Effect
of use of vasopressors in organ donors on immediate function ofdence of ATN. Transplant Proc 24:357, 1992
3. Kadieva VS, Friedmann L, Margolius LP, Jackson SA, Morrell renal allografts. J Transpl Coord 6:215–216, 1996
24. Marshall R, Ahsan N, Dhillon S, Holman M, Yang HC: Ad-DF: The effect of dopamine on graft function in patients undergo-
ing renal transplantation. Anesth Analg 76:362–365, 1993 verse effect of donor vasopressor support on immediate and one-
year kidney allograft function. Surgery 120:663–665, 19964. Grundmann R, Kindler J, Meider G, Stowe H, Sieberth HG,
Pichlmaier H: Dopamine treatment of human cadaver kidney 25. Carlos TM, Clark RS, Franicola-Higgins D, Schiding JK, Ko-
chanek PM: Expression of endothelial adhesion molecules andgraft recipients: A prospectively randomized trial. Klin Wochen-
schr 60:193–197, 1982 recruitment of neutrophils after traumatic brain injury in rats.
J Leukoc Biol 61:279–285, 19975. Maines MD: The heme oxygenase system: A regulator of second
messenger gases. Annu Rev Pharmacol Toxicol 37:517–554, 1997 26. Stanimirovic DB, Wong J, Shapiro A, Durkin JP: Increase in
surface expression of ICAM-1, VCAM-1 and E-selectin in human6. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN:
Bilirubin is an antioxidant of possible physiological importance. cerebromicrovascular endothelial cells subjected to ischemia-like
insults. Acta Neurochir Suppl (Wien) 70:12–16, 1997Science 235:1043–1046, 1987
7. Vogt BA, Shanley TP, Croatt A, Alam J, Johnson KJ, Nath 27. Fortenberry JD, Huber AR, Owens ML: Inotropes inhibit endo-
thelial cell surface adhesion molecules induced by interleukin-1b.KA: Glomerular inflammation induces resistance to tubular injury
Crit Care Med 25:303–308, 1997in the rat: A novel form of acquired, heme oxygenase-dependent
28. Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F,resistance to renal injury. J Clin Invest 98:2139–2145, 1996
Eaton JW, Vercellotti GM: Ferritin: A cytoprotective antioxi-8. Nath KA, Balla G, Vercellotti GM, Balla J, Jacob HS, Levitt
dant stratagem of endothelium. J Biol Chem 267:18148–18153, 1992MD, Rosenberg ME: Induction of heme oxygenase is a rapid,
29. Amersi F, Buelow R, Kato H, Ke B, Coito AJ, Shen XD, Zhaoprotective response in rhabdomyolysis in the rat. J Clin Invest
D, Zaky J, Melinek J, Lassman CR, Kolls JK, Alam J, Ritter90:267–270, 1992
T, Volk HD, Farmer DG, Ghobrial RM, Busuttil RW, Kupiec-9. Hancock WW, Buelow R, Sayegh MH, Turka LA: Antibody-
Weglinski JW: Upregulation of heme oxygenase-1 protects geneti-induced transplant arteriosclerosis is prevented by graft expression
cally fat Zucker rat livers from ischemia/reperfusion injury. J Clinof anti-oxidant and anti-apoptotic genes. Nat Med 4:1392–1396, 1998
Invest 104:1631–1639, 199910. Soares MP, Lin Y, Anrather J, Csizmadia E, Takigami K, Sato
30. Shimizu H, Takahashi T, Suzuki T, Yamasaki A, Fujiwara T,K, Grey ST, Colvin RB, Choi AM, Poss KD, Bach FH: Expression
Odaka Y, Hirakawa M, Fujita H, Akagi R: Protective effect ofof heme oxygenase-1 can determine cardiac xenograft survival.
heme oxygenase induction in ischemic acute renal failure. CritNat Med 4:1073–1077, 1998
Care Med 28:809–817, 200011. Smythies J, Galzigna L: The oxidative metabolism of cathecho-
31. Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ,lamines in the brain: A review. Biochim Biophys Acta 1320:159–
Motterlini R: Heme oxygenase-1-derived bilirubin ameliorates162, 1998
postischemic myocardial dysfunction. Am J Physiol Heart Circ12. Halliwell B, Gutteridge JMC: Free Radicals in Biology and
Physiol 278:H643–H651, 2000Medicine (3rd ed). Oxford, Oxford University Press, 1999
32. Hayashi S, Takamiya R, Yamaguchi T, Matsumoto K, Tojo SJ,13. Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of
Tamatani T, Kitajima M, Makino N, Ishimura Y, Suematsu M:human endothelial cells derived from umbilical veins: Identification
Induction of heme oxygenase-1 suppresses venular leukocyte adhe-by morphologic and immunologic criteria. J Clin Invest 52:2745– sion elicited by oxidative stress: Role of bilirubin generated by the2756, 1973 enzyme. Circ Res 85:663–671, 199914. Yoshida T, Biro P, Cohen T, Muller RM, Shibahara S: Human 33. Land W: The potential impact of the reperfusion injury on acute
heme oxygenase cDNA and induction of its mRNA by hemin. Eur and chronic rejection events following organ transplantation.
J Biochem 171:457–461, 1988 Transplant Proc 26:3169–3171, 1994
15. Tso JY, Sun XH, Kao TH, Reece KS, Wu R: Isolation and charac- 34. Murry CE, Jennings RB, Reimer KA: Preconditioning with ische-
terization of rat and human glyceraldehyde-3-phosphate dehydro- mia: A delay of lethal injury in ischemic myocardium. Circulation
genase cDNAs: Genomic complexity and molecular evolution of 74:1126–1136, 1986
the gene. Nucleic Acids Res 13:2485–2502, 1985 35. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson
16. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn RA, Downey JM: Protection against infarction afforded by precon-
GT, Mullis KB, Erlich HA: Primer-directed enzymatic amplifi- ditioning is mediated by A1 adenosine receptors in rabbit heart.
cation of DNA with a thermostable DNA polymerase. Science Circulation 84:350–356, 1991
239:487–491, 1988 36. Sun JZ, Tang XL, Park SW, Qiu Y, Turrens JF, Bolli R: Evi-
17. Laemmli UK: Cleavage of structural proteins during the assembly dence for an essential role of reactive oxygen species in the genesis
of the head of bacteriophage T4. Nature 227:680–685, 1970 of late preconditioning against myocardial stunning in conscious
18. Matsuoka T: A sedative effect of dopamine on the respiratory pigs. J Clin Invest 97:562–576, 1996
burst in neonatal polymorphonuclear leukocytes. Pediatr Res 28: 37. Xuan YT, Tang XL, Banerjee S, Takano H, Li RC, Han H, Qiu
24–27, 1990 Y, Li JJ, Bolli R: Nuclear factor-kappaB plays an essential role
19. Allen E, Pettigrew A, Frank D, Thompson S, Myers C, Yama- in the late phase of ischemic preconditioning in conscious rabbits.
shita T, Blumer JL: Alterations in dopamine clearance and cate- Circ Res 84:1095–1109, 1999
chol-O-methyltransferase activity by dopamine infusions in chil- 38. Takano H, Manchikalapudi S, Tang XL, Qiu Y, Rizvi A, Jadoon
dren. Crit Care Med 25:181–189, 1997 AK, Zhang Q, Bolli R: Nitric oxide synthase is the mediator
20. Jenner P, Olanow CW: Oxidative stress and the pathogenesis of of late preconditioning against myocardial infarction in conscious
Parkinson’s disease. Neurology 47:S161–S170, 1996 rabbits. Circulation 98:441–449, 1998
